Antiretroviral treatment in resource-poor settings: What can we learn from the existing programmes in Thailand?

AIDS

Volumn 18, Issue SUPPL. 3, 2004, Pages

  Phanuphak, Praphan ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Resource poor countries; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BUDGET; DRUG COST; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORGANIZATION; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SOCIETY; THAILAND;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; BUDGETS; DRUG COSTS; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; LABORATORIES, HOSPITAL; PATIENT COMPLIANCE; THAILAND;

EID: 3843113312     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200406003-00007     Document Type: Review

References (13)

1. Phanuphak P, Lohcharernkul C, Panmoung W, Wilde H. A report of three cases of AIDS in Thailand. Asian Pac J Allergy Immunol 1985, 3:195-199.
2. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, Vanichseni S, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991, 5 (Suppl. 2):S71-S85.
3. The Thai Working Group on HIV/AIDS Projection. Projections for HIV/AIDS in Thailand: 2000-2020. Bangkok: Division of AIDS, Ministry of Public Health, March 2001.
4. Anonymous. AIDS situation in Thailand up to September 30, 2003: Division of Epidemiololgy, Department of Communicable Diseases Control (CDC), Thai Ministry of Public Health. September 2003.
5. World Bank. Thailand's response to AIDS: building on success, confronting the future. World Bank Washington, D.C.; November 2000.
6. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naïve, HIV-infected Thai patients. AIDS 2000, 14:1375-1382.
7. Phanuphak P, Cooper DA, Lange JMA. Clinical trials in Asia 1998. AIDS 1998 12 (Suppl. B): S163-S167.
8. Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). AIDS 2000, 14:1349-1356.
9. Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J AIDS 2001, 27:116-123.
10. Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, et al. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. Vanguard Study Group. AIDS 2000, 14:2509-2513.
11. Ananworanich J, Cheunyam T, Teeratakulpisarn S, Boyd MA, Ruxrungtham K, Lange J, et al. Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet 2004, In press.
12. LaFraniere S. South Africa, in shift, to give AIDS drugs free. International Herald Tribune Friday, 21 November 2003.
13. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:1889-1896.